Abivax (ABVX) Research Hub

Abivax (ABVX) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 86.5 USD (-1.72%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -23.48, market cap 9.58B. This hub links to the full technical, earnings and options research available for ABVX.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, FR
Last close86.5 USD (-1.72%)
52-week range74.79 USD – 147.98 USD
Trend regimeRange
14-day RSI47.1 (Neutral)
Trailing P/E-23.48
Market cap9.58B
Dividend yield0.00%
Next earnings2026-09-14

Available research for ABVX

Earnings

ABVX earnings date and last-quarter result: next report 2026-09-14, last quarter beat, P/E -23.48. Updated 2026-07-23.

Options: Covered Call

Covered Call on ABVX: how it works, illustrative setup around the real 86.5 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on ABVX: how it works, illustrative setup around the real 86.5 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on ABVX: how it works, illustrative setup around the real 86.5 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

ABVX technical analysis: range, last 86.5 USD, RSI 47.1, 52w range 74.79 USD–147.98 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is ABVX in?

Abivax (ABVX) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.

Is ABVX in an uptrend or downtrend?

As of 2026-10-26, ABVX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is ABVX's trailing P/E ratio?

ABVX's trailing P/E is -23.48, with a market cap of 9.58B. See the earnings research page for full valuation detail.

When does ABVX next report earnings?

ABVX is next scheduled to report earnings on 2026-09-14.